2025 Q2 -tulosraportti
217 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 3 000 | - | - | ||
| 2 000 | - | - | ||
| 10 000 | - | - | ||
| 500 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·7 t sittenLove people's comments on my previous post hahaha. It was an April Fool's joke… The girls should of course also have a say. Hope you're enjoying the Easter beers and haven't sold, because this one I'm only selling when it's at 30-40.
·7 t sittenHold until they are acquired. Then you earn even more. But yeah yeah everyone naturally makes their own decision.
·4 t sittenHow can we know that they will be? And do you know when?
·7 t sittenWill CRNA present data from this study with big pharma now in April, or do I remember incorrectly? I think I read that preliminary results/tests were good, but that more results would come later, estimated April this year.. Does anyone know? https://live.euronext.com/nb/listview/company-press-release/226095#CompanyPressRelease-12847894
·8 t sittenRegarding speculations about acquisition prices, one can calculate what the share price would be relative to the purchase price, but there's something entirely different that I don't think is being discussed or thought about much. When we talk about Circio and their product, it should by now be clear to everyone that it is in the revolutionary category, provided it can be made to work. An incredibly effective platform for delivering, from what I understand, almost any form of vaccine or gene-therapeutic based medicine; it's about tweaking it for the individual. Is there fundamentally not MUCH greater economic potential in it if Circio doesn't sell, but instead licenses their cRNA platform and, as it were, produces customized delivery platforms for the companies that can benefit from it? If one has something so revolutionary, surely that must be a possible strategy? Perhaps I'm overlooking something here, but immediately it seems cheap when we talk about a share price of 200 kr in connection with an acquisition, set against the other model?·6 t sittenGood point, I immediately think it's about patience. If an acquisition were to happen, it would probably be within 1.5 years. And if the price then just jumps up to 200kr, one would have earned a lot of money very quickly. By licensing, it would probably take a bit longer to get the price up there, but as you yourself say, the price can probably go much higher in the long run.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
217 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenLove people's comments on my previous post hahaha. It was an April Fool's joke… The girls should of course also have a say. Hope you're enjoying the Easter beers and haven't sold, because this one I'm only selling when it's at 30-40.·7 t sittenHold until they are acquired. Then you earn even more. But yeah yeah everyone naturally makes their own decision.·4 t sittenHow can we know that they will be? And do you know when?
- ·7 t sittenWill CRNA present data from this study with big pharma now in April, or do I remember incorrectly? I think I read that preliminary results/tests were good, but that more results would come later, estimated April this year.. Does anyone know? https://live.euronext.com/nb/listview/company-press-release/226095#CompanyPressRelease-12847894
- ·8 t sittenRegarding speculations about acquisition prices, one can calculate what the share price would be relative to the purchase price, but there's something entirely different that I don't think is being discussed or thought about much. When we talk about Circio and their product, it should by now be clear to everyone that it is in the revolutionary category, provided it can be made to work. An incredibly effective platform for delivering, from what I understand, almost any form of vaccine or gene-therapeutic based medicine; it's about tweaking it for the individual. Is there fundamentally not MUCH greater economic potential in it if Circio doesn't sell, but instead licenses their cRNA platform and, as it were, produces customized delivery platforms for the companies that can benefit from it? If one has something so revolutionary, surely that must be a possible strategy? Perhaps I'm overlooking something here, but immediately it seems cheap when we talk about a share price of 200 kr in connection with an acquisition, set against the other model?·6 t sittenGood point, I immediately think it's about patience. If an acquisition were to happen, it would probably be within 1.5 years. And if the price then just jumps up to 200kr, one would have earned a lot of money very quickly. By licensing, it would probably take a bit longer to get the price up there, but as you yourself say, the price can probably go much higher in the long run.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 3 000 | - | - | ||
| 2 000 | - | - | ||
| 10 000 | - | - | ||
| 500 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
217 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenLove people's comments on my previous post hahaha. It was an April Fool's joke… The girls should of course also have a say. Hope you're enjoying the Easter beers and haven't sold, because this one I'm only selling when it's at 30-40.·7 t sittenHold until they are acquired. Then you earn even more. But yeah yeah everyone naturally makes their own decision.·4 t sittenHow can we know that they will be? And do you know when?
- ·7 t sittenWill CRNA present data from this study with big pharma now in April, or do I remember incorrectly? I think I read that preliminary results/tests were good, but that more results would come later, estimated April this year.. Does anyone know? https://live.euronext.com/nb/listview/company-press-release/226095#CompanyPressRelease-12847894
- ·8 t sittenRegarding speculations about acquisition prices, one can calculate what the share price would be relative to the purchase price, but there's something entirely different that I don't think is being discussed or thought about much. When we talk about Circio and their product, it should by now be clear to everyone that it is in the revolutionary category, provided it can be made to work. An incredibly effective platform for delivering, from what I understand, almost any form of vaccine or gene-therapeutic based medicine; it's about tweaking it for the individual. Is there fundamentally not MUCH greater economic potential in it if Circio doesn't sell, but instead licenses their cRNA platform and, as it were, produces customized delivery platforms for the companies that can benefit from it? If one has something so revolutionary, surely that must be a possible strategy? Perhaps I'm overlooking something here, but immediately it seems cheap when we talk about a share price of 200 kr in connection with an acquisition, set against the other model?·6 t sittenGood point, I immediately think it's about patience. If an acquisition were to happen, it would probably be within 1.5 years. And if the price then just jumps up to 200kr, one would have earned a lot of money very quickly. By licensing, it would probably take a bit longer to get the price up there, but as you yourself say, the price can probably go much higher in the long run.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 3 000 | - | - | ||
| 2 000 | - | - | ||
| 10 000 | - | - | ||
| 500 | - | - |
Välittäjätilasto
Dataa ei löytynyt